Results 101 to 110 of about 21,287 (236)
Introduction Maintaining fluid intake sufficient to reduce arginine vasopressin (AVP) secretion has been hypothesised to slow kidney cyst growth in autosomal dominant polycystic kidney disease (ADPKD).
A. Wong +33 more
semanticscholar +1 more source
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure.
Christopher M Blanchette +7 more
doaj +1 more source
Chronic subdural haematoma and arachnoid cyst in autosomal dominant polycystic kidney disease (ADPKD) [PDF]
We present the unusual association between chronic subdural haematoma (CSDH), intracranial arachnoid cyst and autosomal dominant polycystic kidney disease (ADPKD) in a 27-year-old man. CSDH is a documented complication of intracranial arachnoid cyst, the
Yiu, WF, Leung, GKK
core +1 more source
Describing and Explaining ADPKD Variability Within Families
[Extract] Differences in the experience of kidney disease and other complications of autosomal dominant polycystic kidney disease (ADPKD) within families has long been a clinical conundrum.1 Where large cohort studies have previously identified key ...
Achi, Sai Santhoshini +1 more
core +1 more source
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple, large renal cysts and impaired kidney function. Although the reason for the development of kidney cysts is unknown, ADPKD is associated with cell cycle arrest ...
Funda Sarı +6 more
doaj +1 more source
Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is a genetic ciliopathy disease characterized by progressive formation and enlargement of cysts in multiple organs.
A. Makhlough +8 more
semanticscholar +1 more source
Tolvaptan slows disease progression in late-stage ADPKD
New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care ...
Ong, A.C.M.
core +1 more source
Autosomal dominant polycystic kidney disease (ADPKD), one of the most common genetic disorders, is caused by mutations in the PKD1 or PKD2 gene.
Yingying He +6 more
doaj +1 more source
A pilot study to evaluate tolerability and safety of a modified Atkins diet in ADPKD patients
Background Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the fourth cause of end stage renal disease (ESRD) and urgently requires the development of effective therapeutic treatments.
F. Testa +7 more
semanticscholar +1 more source

